{"success":true,"data":{"pressRelease":{"id":"134312","rtpr_id":"nGNX9Pm8ZG","ticker":"SPRO","exchange":"NASDAQ","all_tickers":["SPRO"],"title":"Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference","author":"Globe Newswire","published_at":"2026-09-02T20:01:00.172Z","article_body":"CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=6mnS15iEkuFmGvGJuWLwc_mL5i4TLe33VVOGHZLWjIQ6rINmDR9ii8hofpAyeNgnWyiWkTj5I5anVvDsUrNUzyj93Gz_mxo05j41_fvSopw=)\n(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines in immunology and inflammation, today\nannounced that Esther Rajavelu, President and Chief Executive Officer, will\npresent at the H.C. Wainwright 28th Annual Global Healthcare Conference, to be\nheld in New York City, September 14th -16th, 2026. Spero's leadership team\nwill also be available for one-on-one meetings at the conference.\n\nPresentation Details:\n\n H.C. Wainwright 28 (th)Annual Global Investment Conference                                                         \n Company Presentation:  September 15, 2026                                                                          \n Time:                  1:30 PM ET                                                                                  \n Location:              New York, NY                                                                                \n Webcast Link:          Company Presentation (https://journey.ct.events/view/e9830fd5-06fd-4613-85b2-0b7afe4a1451)  \n                                                                                                                    \n\nThe webcast may also be accessed through Spero's website on the Events +\nPresentations\n(https://www.globenewswire.com/Tracker?data=c9snYASJcRXmkXOvZOdn7CRYr9jVn8_O17EB41ODERRIMKkKuYLV9cZa2tmqy_ILX_z-O8zpV_uSDpvAgUYe6Av_UBRdibIzIdfHP3xAXqL20vkbfIE4tLF4rP6xcpgccrkcOuym_-iV1q4bxAVKSA==)\npage. A replay of the webcast will be available for approximately 90 days\nfollowing the conference. To request a meeting or for more details about the\nconference please reach out to your institutional contact at H.C. Wainwright.\n\nAbout Spero Therapeutics\n\nSpero Therapeutics is a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines for patients with serious immune-mediated\ndiseases. The company’s lead program, SP001, is a third-generation,\nFc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related\ndisease, with potential for development in additional immunological &\ninflammatory diseases. For more information, visit www.sperotx.com.\n\nInvestor Relations Contact:\nShai Biran, PhD\nSpero Therapeutics\nIR@Sperotx.com\n\nMedia Inquiries:\nmedia@sperotx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/908599b7-dec6-4771-91e4-e8e60bea78e6)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9Pm8ZG","title":"Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference","author":"Globe Newswire","ticker":"SPRO","created":"2026-09-02T20:01:00.172Z","tickers":["SPRO"],"exchange":"NASDAQ","article_body":"CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=6mnS15iEkuFmGvGJuWLwc_mL5i4TLe33VVOGHZLWjIQ6rINmDR9ii8hofpAyeNgnWyiWkTj5I5anVvDsUrNUzyj93Gz_mxo05j41_fvSopw=)\n(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines in immunology and inflammation, today\nannounced that Esther Rajavelu, President and Chief Executive Officer, will\npresent at the H.C. Wainwright 28th Annual Global Healthcare Conference, to be\nheld in New York City, September 14th -16th, 2026. Spero's leadership team\nwill also be available for one-on-one meetings at the conference.\n\nPresentation Details:\n\n H.C. Wainwright 28 (th)Annual Global Investment Conference                                                         \n Company Presentation:  September 15, 2026                                                                          \n Time:                  1:30 PM ET                                                                                  \n Location:              New York, NY                                                                                \n Webcast Link:          Company Presentation (https://journey.ct.events/view/e9830fd5-06fd-4613-85b2-0b7afe4a1451)  \n                                                                                                                    \n\nThe webcast may also be accessed through Spero's website on the Events +\nPresentations\n(https://www.globenewswire.com/Tracker?data=c9snYASJcRXmkXOvZOdn7CRYr9jVn8_O17EB41ODERRIMKkKuYLV9cZa2tmqy_ILX_z-O8zpV_uSDpvAgUYe6Av_UBRdibIzIdfHP3xAXqL20vkbfIE4tLF4rP6xcpgccrkcOuym_-iV1q4bxAVKSA==)\npage. A replay of the webcast will be available for approximately 90 days\nfollowing the conference. To request a meeting or for more details about the\nconference please reach out to your institutional contact at H.C. Wainwright.\n\nAbout Spero Therapeutics\n\nSpero Therapeutics is a clinical-stage biopharmaceutical company focused on\nadvancing next-generation medicines for patients with serious immune-mediated\ndiseases. The company’s lead program, SP001, is a third-generation,\nFc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related\ndisease, with potential for development in additional immunological &\ninflammatory diseases. For more information, visit www.sperotx.com.\n\nInvestor Relations Contact:\nShai Biran, PhD\nSpero Therapeutics\nIR@Sperotx.com\n\nMedia Inquiries:\nmedia@sperotx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/908599b7-dec6-4771-91e4-e8e60bea78e6)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-02T20:01:00.206065048Z","server_sent_at_ms":1788379260206},"received_at":"2026-09-02T20:01:00.371Z","source_url":null},"analysis":{"id":"123214","press_release_id":"134312","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Spero Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, with the company presentation scheduled for September 15, 2026 at 1:30 PM ET.\n\nPresident and CEO Esther Rajavelu will deliver the presentation, and Spero's leadership team will be available for one-on-one meetings; a webcast with an approximately 90-day replay will be accessible via the company's website.\n\nThis is routine investor-relations scheduling with no new clinical or financial data; Spero's lead program remains SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance -- only worth monitoring if the September 15 webcast surfaces new SP001 pipeline color."},"keyFigures":{},"namedEntities":{"people":[{"name":"Esther Rajavelu","role":"President and Chief Executive Officer"},{"name":"Shai Biran, PhD","role":"Investor Relations contact"}],"products":["SP001"],"companies":[{"name":"Spero Therapeutics, Inc.","ticker":"SPRO","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference host / investment bank"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Boilerplate investor-conference scheduling announcement with no new clinical, financial, or strategic information disclosed."},"tickerRelevance":{"others":[],"primary":"SPRO"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-investor-conference-scheduling","issuerAuthored":true,"newInformation":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Spero Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City, with the company presentation scheduled for September 15, 2026 at 1:30 PM ET.\n\nPresident and CEO Esther Rajavelu will deliver the presentation, and Spero's leadership team will be available for one-on-one meetings; a webcast with an approximately 90-day replay will be accessible via the company's website.\n\nThis is routine investor-relations scheduling with no new clinical or financial data; Spero's lead program remains SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease.","key_figures":{},"named_entities":{"people":[{"name":"Esther Rajavelu","role":"President and Chief Executive Officer"},{"name":"Shai Biran, PhD","role":"Investor Relations contact"}],"products":["SP001"],"companies":[{"name":"Spero Therapeutics, Inc.","ticker":"SPRO","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference host / investment bank"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T20:03:51.267Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-investor-conference-scheduling","issuerAuthored":true,"newInformation":false}},"durationMs":34663,"modelName":"glm-4.7"}}